At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DVAX Dynavax
Post-Market Trading 11-14 17:00:58 EST
13.39
-0.13
-0.96%
盘后13.00
-0.39-2.91%
16:17 EST
High13.71
Low13.37
Vol2.60M
Open13.58
D1 Closing13.52
Amplitude2.51%
Mkt Cap1.76B
Tradable Cap1.52B
Total Shares131.45M
T/O35.06M
T/O Rate2.30%
Tradable Shares113.20M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Dynavax Technologies Corp Entered $100 Million Accelerated Share Repurchase Agreement With Goldman Sachs & Co. LLC
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.